Adcirca (Tadalafil)



Indications and Reactions:

Role Indications Reactions
Secondary
Pulmonary Arterial Hypertension 50.0%
Chronic Pulmonary Heart Disease 25.0%
Pulmonary Hypertension 25.0%
Diarrhoea 25.0%
Fluid Retention 25.0%
Neutropenia 25.0%
Pneumonia 25.0%
Concomitant
Pulmonary Arterial Hypertension 63.8%
Cor Pulmonale Chronic 15.1%
Pulmonary Hypertension 8.6%
Primary Pulmonary Hypertension 7.2%
Pulmonary Arterial Hypertension 0.7%
Chronic Pulmonary Heart Disease 0.7%
Idiopathic Pulmonary Arterial Hypertension 0.7%
Portopulmonary Hypertension 0.7%
Product Used For Unknown Indication 0.7%
Pulmonary Hypertension Secondary 0.7%
Systemic Lupus Erythematosus 0.7%
Systemic Sclerosis 0.7%
Death 22.4%
Device Related Infection 13.3%
Pulmonary Hypertension 6.1%
Syncope 6.1%
Vomiting 6.1%
Infusion Site Infection 5.1%
Pulmonary Arterial Hypertension 5.1%
Dyspnoea 4.1%
Renal Failure 4.1%
Fluid Overload 3.1%
Medical Device Complication 3.1%
Nausea 3.1%
Pulseless Electrical Activity 3.1%
Sepsis 3.1%
Cerebrovascular Accident 2.0%
Diarrhoea 2.0%
Fluid Retention 2.0%
Hypotension 2.0%
Infusion Site Pain 2.0%
Injection Site Infection 2.0%